Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.83
-0.24 (-2.65%)
At close: Apr 28, 2026, 4:00 PM EDT
8.89
+0.06 (0.68%)
Pre-market: Apr 29, 2026, 8:44 AM EDT
Kura Oncology Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Kura Oncology stock have an average target of 25.56, with a low estimate of 11 and a high estimate of 40. The average target predicts an increase of 189.47% from the current stock price of 8.83.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Kura Oncology stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +160.48% | Apr 14, 2026 |
| Mizuho | Mizuho | Buy Maintains $30 → $25 | Buy | Maintains | $30 → $25 | +183.13% | Mar 24, 2026 |
| UBS | UBS | Strong Buy Maintains $16 → $15 | Strong Buy | Maintains | $16 → $15 | +69.88% | Mar 13, 2026 |
| Wedbush | Wedbush | Buy Maintains $38 → $36 | Buy | Maintains | $38 → $36 | +307.70% | Mar 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +353.00% | Jan 13, 2026 |
Financial Forecast
Revenue This Year
86.57M
from 67.48M
Increased by 28.28%
Revenue Next Year
178.65M
from 86.57M
Increased by 106.37%
EPS This Year
-3.88
from -3.18
EPS Next Year
-2.89
from -3.88
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 119.7M | 294.7M | ||||||
| Avg | 86.6M | 178.7M | ||||||
| Low | 49.0M | 59.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 77.4% | 240.4% | ||||||
| Avg | 28.3% | 106.4% | ||||||
| Low | -27.4% | -31.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.43 | -1.51 | ||||||
| Avg | -3.88 | -2.89 | ||||||
| Low | -4.21 | -3.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.